Gan Partners, together with its funds ( is pleased to announce its investment in Adenocyte™ ( a medical technology company ...
Inflammatory bowel disease (IBD) is an umbrella term for Crohn's disease and ulcerative colitis, which both involve chronic inflammation ... | Cell And Molecular Biology ...
Using spatial multi-omics, researchers identified shifting macrophage populations in MASLD progression, identifying markers to aid patient stratification in clinical trials.
A new review highlights how synthetic biology, AI, and spatial omics could transform ligand-receptor discovery from one-by-one searches into network-level mapping.
A new review highlights how synthetic biology, AI, and spatial omics could transform ligand-receptor discovery from one-by-one searches into ...
A novel spatial transcriptomics atlas developed by Northwestern Medicine scientists may improve the understanding of niche cellular interactions in the gastrointestinal tract that promote the ...
The field of cancer immunotherapy has witnessed remarkable progress over the past decade, offering durable benefits for subsets of patients across multiple ...
Recent decades have witnessed unprecedented scientific growth driven by the convergence of clinical medicine, life sciences, ...
Multidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and ...
Owkin has signed a new multi-year agreement with AstraZeneca centered around K Pro, Owkin’s agentic AI platform designed for pharmaceutical research and strategic decision-making. Under the three-year ...
MarketBeat on MSN
10x Genomics Q1 earnings call highlights
Strategic Buy Lights Up This Biotech Stock: Time to Invest? 10x Genomics (NASDAQ:TXG) reported a first-quarter revenue ...
Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 4.8% year on year to $1.09 billion. The company’s full-year revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results